Potential Pharmacological Chaperones for Cystathionine Beta-Synthase-Deficient Homocystinuria

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• Classical homocystinuria (HCU) results from loss-of-function mutations in the cystathionine beta-synthase (CBS) gene.
• Mutations often cause CBS misfolding and degradation, leading to toxic homocysteine accumulation.
• Current treatments partially effective; novel therapeutic avenues are needed.

Purpose of the Study:

• To review the structural and functional aspects of CBS.
• To explore therapeutic strategies targeting CBS misfolding in HCU.
• To highlight recent advances in understanding CBS regulation and potential drug development.

Main Methods:

• Review of existing literature on CBS structure, function, and HCU.
• Analysis of studies on small molecule chaperones and proteasome inhibitors in HCU models.
• Discussion of recent crystallographic data and computational modeling approaches.

Main Results:

• CBS function depends on cofactors heme, PLP, and SAM, with complex allosteric regulation.
• Chemical chaperones and proteasome inhibitors show promise in rescuing mutant CBS activity in vitro and in vivo.
• Structural insights facilitate understanding of misfolding mechanisms.

Conclusions:

• Targeting CBS misfolding offers a promising alternative therapeutic strategy for HCU.
• Development of CBS-specific compounds through screening and modeling is a key future direction.
• Improved folding, stability, and activity of mutant CBS could significantly benefit HCU patients.